BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is continuing preparations for the Phase 3b ENDURANCE trial of NurOwn ® for the treatment of patients with amyotrophic lateral sclerosis (ALS). In May ...
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The ...
BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is developing NurOwn as a treatment for patients with amyotrophic lateral sclerosis (ALS). The company recently published results from the Phase 3 ...
On July 3, 2025, a Citizen’s Petition was filed with the U.S. Food and Drug Administration in which the petitioners, a group consisting mostly of amyotrophic lateral sclerosis (ALS) patients who have ...
) has been revised to $17.34 / share. This is a decrease of 13.95% from the prior estimate of $20.15 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...
READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENERATIVE DISEASE STEM CELLS & ALS/MND/LOU GEHRIG'S HERE Post hoc analysis of BCLI's PIII early stage (mild ...
The average one-year price target for Brainstorm Cell Therapeutics (NasdaqCM:BCLI) has been revised to 2.55 / share. This is an increase of 150.00% from the prior estimate of 1.02 dated March 28, 2024 ...
Brainstorm Cell Therapeutics (NASDAQ: BCLI) stock is up 47% premarket. BCLI stock rising is one of those things that a sober reading of the objective evidence would not lead us to expect. Therefore we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results